secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001831283-23-000107
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q2 2023 net loss narrows to $21.6M; cash $267.3M; mavacamten NDA under priority review in China
--------------------------------------------------------------------------------

- Net loss $21.6M in Q2 2023 vs $42.4M in Q2 2022; R&D expenses fell to $9.5M from $28.6M.
- Cash, equivalents and marketable securities $267.3M at June 30, 2023; runway into first half 2025.
- Mavacamten NDA accepted with priority review by China NMPA; approved in Singapore and Macau.
- Phase 3 EXPLORER-CN met primary endpoint; data to be presented at ESC Congress 2023.
- TP-03 Phase 3 LIBRA fully enrolled; infigratinib Phase 2a in gastric cancer showed 25% ORR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000107/0001831283-23-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000107/lian-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer